Effect of Age on the Time of Neutropenia after Initial Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2022.01.008
- Author:
Xiao-Yan JIA
1
;
Lin CHEN
1
;
Xu-Dong WEI
2
,
3
Author Information
1. Department of Hematology, Henan Tumor Hospital, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China.
2. Department of Hematology, Henan Tumor Hospital, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China,E-mail: weixudong63@
3. com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
age;
neutropenia
- MeSH:
Adolescent;
Adult;
Aged;
Humans;
Induction Chemotherapy;
Leukemia, Myeloid, Acute/drug therapy*;
Male;
Middle Aged;
Mutation;
Neutropenia;
Prognosis;
Remission Induction;
Retrospective Studies;
Young Adult;
fms-Like Tyrosine Kinase 3
- From:
Journal of Experimental Hematology
2022;30(1):43-48
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the effect of age on the time of neutropenia after initial induction therapy for newly diagnosed acute myeloid leukemia (AML) patients.
METHODS:Data of 18-65 years old AML patients treated in our hospital from Junuary 2015 to July 2020 were retrospectively analyzed. The clinical characteristics, time of neutropenia after initial induction treatment, early responses, and related influencing factors for the time of neutropenia were analyzed and compared between 18-40 years old group and 41-65 years old group.
RESULTS:There were 112 patients enrolled in this study, including 66 (58.9%) males, and their median age was 46 years old. Compared with 18-40 years old group, the incidence of FLT3-ITD gene mutation increased (P=0.039) but core binding factor (CBF) decreased (P=0.003) significantly in 41-65 years old group. The incidence of neutropenia was 97.3%, and the average time was (18.70±1.192) days. The time of neutropenia was (21.43±1.736) days in 41-65 years old group, which was longer than (14.91±1.356) days in 18-40 years old group (P=0.006). The time of neutropenia in CBF positive group was shorter than that in negative group (P=0.012), as well as in patients with remission (CR+CRi) (≤ 2 courses) than those with non-remission (NR) (P=0.024), while in high-risk group was longer than that in low-risk group (P=0.040). Multivariate analysis showed that age, FLT3-ITD gene mutation positive, and non-remission (NR) after two courses of treatment were independent risk factors for the time of neutropenia.
CONCLUSION:In non-elderly patients with newly diagnosed AML, age is an influencing factor for the time of neutropenia. Key words ;
